- Company
- FDA grants ODD to LG Chem’s oral genetic obesity drug
- by Chon, Seung-Hyun Jun 20, 2022 06:03am
- LG Chem announced on the 16th that the US Food and Drug Administration has been additionally granted orphan drug status to its new genetic obesity drug ‘LB54640.’ The FDA has recently designated LB54640 as an orphan drug for the treatment of pro-opiomelanocortin (POMC) deficiency.’ The FDA has been operating an Orphan Drug Designat
- Company
- GC Pharma leads 300 billion flu vaccine market
- by Nho, Byung Chul Jun 15, 2022 07:48pm
- SK Chemicals and GC Pharma are competing in the private 4-valent influenza (flu) vaccine market with an external banding of 200 billion won, the survey showed. SK Chemical's SKY Cellflu Quardrient and GC Flu Quardrient ranked first and second in the private distribution flu vaccine for the past three years (2018, 2019, 2020), with performances o
- Company
- Samsung Bioepis Announces Phase 3 Results of Soliris Similar
- by Kim, Jin-Gu Jun 15, 2022 05:50am
- Samsung Bioepis announced on the 13th that it has unveiled the results of phase 3 clinical trials of Soliris (Eculizumab) biosimilar SB12 through the EHA annual academic conference held in Austria from the 9th to the 12th. SB12 is the seventh biosimilar developed by Samsung Bioepis. It is the first blood disease treatment. The original Sol
- Company
- Sales of topical minoxidil rise with interest in hair loss
- by Jun 14, 2022 06:04am
- The market for minoxidil topical solutions that are applied directly to the scalp continued on its strong growth, with marked growth shown by the foam-type Rogaine Foam among the three major products in the market. According to the market research institution IQVIA on the 14th, the minoxidil topical solution market had raised &8361;4.6 b
- Company
- Lilly Korea has entered into negotiations on Emgality
- by Eo, Yun-Ho Jun 14, 2022 06:04am
- CGRP target migraine drug Emgality is in the final stage for insurance benefit registration. According to related industries, Emgality, a target migraine treatment for CGRP (Calcitoninogen-related peptide) by Lilly Korea, recently began negotiations with the NHIS on drug prices. Considering the deadline for negotiations, a conclusion is ex
- Company
- Whether Gardasil 9's supply price increase is reasonable
- by Jun 14, 2022 06:04am
- In order to improve the accessibility of vaccines monopolized by foreign companies, it was suggested that reasonable pricing should be monitored and institutional support measures for self-reliance should be actively reviewed. The Korea Biotechnology Industry Organization Bioeconomic Research Center said in a report titled "Controversy ove
- Company
- Hanall Biopharma to expand HL161 development in earnest
- by Chon, Seung-Hyun Jun 10, 2022 05:44am
- Hanall Biopharma announced on the 9th that its U.S. partner Imunovant will expand the development of HL161 (code name IMVT-1401), which is being developed as a SC autoimmune treatment. Phase 3 clinical trials for severe work history will begin this month and the results of the top line in 2024 will be confirmed. According to Immunovant, there
- Company
- Exports of CKD·Dong-A ST's antianemic biosimilars increase
- by Chon, Seung-Hyun Jun 10, 2022 05:43am
- The biosimilar products developed by Chong Kun Dang and Dong-A ST are starting to make their way into the overseas market, with its Nesp biosimilars starting to generate sales in earnest abroad. Although the companies’ products did not show explosive growth upon entry, the products are increasing their presence in the market. According to th
- Company
- Sanofi & 4 other companies will participate in NIP
- by Lee, Tak-Sun Jun 10, 2022 05:42am
- Unlike the previous year, Sanofi Pasteur is expected to participate as a new business operator and Ilyang Pharmaceutical is expected to be excluded. As a result of the bidding conducted through the Nara Market of the Public Procurement Service on the 9th, Sanofi Pasteur was selected as the first choice by writing the lowest price of 14,433
- Company
- Hanmi’s new biologic receives orphan designation in Europe
- by Chon, Seung-Hyun Jun 10, 2022 05:42am
- New drug products being developed by Hanmi Pharmaceutical have received a total of 20 orphan drug designations from regulatory authorities in Korea and abroad. Hanmi Pharmaceutical announced on the 9th that the European Medicines Agency granted an orphan drug designation for its new triple action biologic drug LAPS Triple Agonist (HM15211)
